Signal transduction via guanine nucleotide binding proteins (G proteins) is crucial in regulation of cardiovascular, neural, endocrine, and immune cell function as well as in cell growth and differentiation. It has been increasingly recognized that turning off cellular signals is as important as turning them on. This is evident in the function of the novel protein family, regulators of G protein signaling (RGS proteins). They are responsible for the subsecond turn-off of G protein regulated potassium channels in heart and strongly inhibit Gi and Gq signal transduction pathways. While much is known about the biochemistry of RGS proteins, little is known about their in vivo functions or their potential as targets of drug design. We have developed two mouse models in which Gi family G proteins are mutated to prevent RGS action (Galpha-i2 and G-alpha-o, G184S). The G-alpha-i2[G184S/G184S]mouse shows dramatic alterations in cardiovascular, central nervous system, hematologic, and metabolic processes. In this proposal, we will ask """"""""What are the roles of G-alpha subunits and RGS proteins in cardiovascular and metabolic function?"""""""" by use of these RGS insensitive G-alpha-i2 and G-alpha-o mouse models and RNAi-mediated suppression of RGS activity. Specifically, we will test role of RGS proteins in cardiac automaticity and ischemic injury. We will also examine RGS action and its effects on drugs controlling adipocyte function and glucose metabolism in vivo. These studies should permit a better understanding of the broad role of RGS proteins in the physiology of heart and adipose tissue and will evaluate the potential of RGS proteins as a novel target of drug action in cardioprotection, glucose homeostasis, and lipid metabolism. Relevance: Cardiovascular and metabolic diseases including diabetes and obesity are major killers in the United States. The pharmaceutical industry focuses on the limited range of therapeutic targets that they consider tractable. Our study will explore the function of a poorly understood but functionally important protein family involved in heart and fat tissue function. The ultimate goal is to define their potential as therapeutic targets in heart disease, obesity, and diabetes. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM039561-19
Application #
7289727
Study Section
Hypertension and Microcirculation Study Section (HM)
Program Officer
Dunsmore, Sarah
Project Start
1988-12-01
Project End
2010-02-28
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
19
Fiscal Year
2007
Total Cost
$604,402
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Pharmacology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Rorabaugh, Boyd R; Chakravarti, Bandana; Mabe, Nathaniel W et al. (2017) Regulator of G Protein Signaling 6 Protects the Heart from Ischemic Injury. J Pharmacol Exp Ther 360:409-416
Feng, Huijie; Sjögren, Benita; Karaj, Behirda et al. (2017) Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations. Neurology 89:762-770
Evelyn, Chris R; Lisabeth, Erika M; Wade, Susan M et al. (2016) Small-Molecule Inhibition of Rho/MKL/SRF Transcription in Prostate Cancer Cells: Modulation of Cell Cycle, ER Stress, and Metastasis Gene Networks. Microarrays (Basel) 5:
Sjögren, Benita; Parra, Sergio; Atkins, Kevin B et al. (2016) Digoxin-Mediated Upregulation of RGS2 Protein Protects against Cardiac Injury. J Pharmacol Exp Ther 357:311-9
Blazer, Levi L; Storaska, Andrew J; Jutkiewicz, Emily M et al. (2015) Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors. ACS Chem Neurosci 6:911-9
Parra, Sergio; Huang, Xinyan; Charbeneau, Raelene A et al. (2014) Conditional disruption of interactions between G?i2 and regulator of G protein signaling (RGS) proteins protects the heart from ischemic injury. BMC Pharmacol Toxicol 15:29
Lamberts, Jennifer T; Smith, Chelsea E; Li, Ming-Hua et al. (2013) Differential control of opioid antinociception to thermal stimuli in a knock-in mouse expressing regulator of G-protein signaling-insensitive G?o protein. J Neurosci 33:4369-77
Kaur, Kuljeet; Parra, Sergio; Chen, Rong et al. (2012) G?i2 signaling: friend or foe in cardiac injury and heart failure? Naunyn Schmiedebergs Arch Pharmacol 385:443-53
Waterson, Rachael E; Thompson, Corbin G; Mabe, Nathaniel W et al. (2011) G?(i2)-mediated protection from ischaemic injury is modulated by endogenous RGS proteins in the mouse heart. Cardiovasc Res 91:45-52
Sjogren, Benita; Neubig, Richard R (2010) Thinking outside of the ""RGS box"": new approaches to therapeutic targeting of regulators of G protein signaling. Mol Pharmacol 78:550-7

Showing the most recent 10 out of 29 publications